Stem cell governance in China: from bench to bedside?

Developing stem cell translational medicine and regulating the clinical translation of stem cells will pose great challenges in the future. This article will present three cases in China and show how each mobilized various strategies to bring stem cell science to treatments and commercialization and the problems encountered in the process. The case studies will show that translational research involves multiple interactions between different actors and requires new modes of governance. In China, as in other countries, the regulatory context for translational stem cell research is far from clear, but the absence of state regulation has not led to a oWild Easto regulatory constellation, but rather to individualized regulatory strategies by a variety of stakeholders.